Mirum succeeds in rare liver disease trial; First Tracks delivers in celiac
Mirum Pharmaceuticals’ late-stage win in ultra-rare liver diseases: The company’s ileal bile acid transporter inhibitor Livmarli significantly reduced cholestatic pruritus versus placebo in patients with cholestatic liver diseases, including biliary atresia ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.